View in EDS

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.

Saved in:
Bibliographic Details
Title: Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Authors: Tiedt R; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., King FJ; Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA., Stamm C; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Niederst MJ; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA. Electronic address: matt.niederst@novartis.com., Delach S; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Zumstein-Mecker S; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Meltzer J; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Mulford IJ; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Labrot E; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Engstler BS; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Baltschukat S; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Kerr G; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Golji J; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Wyss D; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Schnell C; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Ainscow E; Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA., Engelman JA; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Sellers WR; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Barretina J; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Caponigro G; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Porta DG; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.
Source: Cell reports [Cell Rep] 2023 Apr 25; Vol. 42 (4), pp. 112297. Date of Electronic Publication: 2023 Mar 23.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36961816
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tiedt+R%22">Tiedt R</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22King+FJ%22">King FJ</searchLink>; Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Stamm+C%22">Stamm C</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Niederst+MJ%22">Niederst MJ</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA. Electronic address: matt.niederst@novartis.com.<br /><searchLink fieldCode="AU" term="%22Delach+S%22">Delach S</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Zumstein-Mecker+S%22">Zumstein-Mecker S</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Meltzer+J%22">Meltzer J</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Mulford+IJ%22">Mulford IJ</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Labrot+E%22">Labrot E</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Engstler+BS%22">Engstler BS</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Baltschukat+S%22">Baltschukat S</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kerr+G%22">Kerr G</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Golji+J%22">Golji J</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wyss+D%22">Wyss D</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Schnell+C%22">Schnell C</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Ainscow+E%22">Ainscow E</searchLink>; Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Engelman+JA%22">Engelman JA</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sellers+WR%22">Sellers WR</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Barretina+J%22">Barretina J</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Caponigro+G%22">Caponigro G</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Porta+DG%22">Porta DG</searchLink>; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101573691%22">Cell reports</searchLink> [Cell Rep] 2023 Apr 25; Vol. 42 (4), pp. 112297. <i>Date of Electronic Publication: </i>2023 Mar 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101573691 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2211-1247 (Electronic) <i>NLM ISO Abbreviation: </i>Cell Rep <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36961816
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.celrep.2023.112297
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 112297
    Titles:
      – TitleFull: Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tiedt R
      – PersonEntity:
          Name:
            NameFull: King FJ
      – PersonEntity:
          Name:
            NameFull: Stamm C
      – PersonEntity:
          Name:
            NameFull: Niederst MJ
      – PersonEntity:
          Name:
            NameFull: Delach S
      – PersonEntity:
          Name:
            NameFull: Zumstein-Mecker S
      – PersonEntity:
          Name:
            NameFull: Meltzer J
      – PersonEntity:
          Name:
            NameFull: Mulford IJ
      – PersonEntity:
          Name:
            NameFull: Labrot E
      – PersonEntity:
          Name:
            NameFull: Engstler BS
      – PersonEntity:
          Name:
            NameFull: Baltschukat S
      – PersonEntity:
          Name:
            NameFull: Kerr G
      – PersonEntity:
          Name:
            NameFull: Golji J
      – PersonEntity:
          Name:
            NameFull: Wyss D
      – PersonEntity:
          Name:
            NameFull: Schnell C
      – PersonEntity:
          Name:
            NameFull: Ainscow E
      – PersonEntity:
          Name:
            NameFull: Engelman JA
      – PersonEntity:
          Name:
            NameFull: Sellers WR
      – PersonEntity:
          Name:
            NameFull: Barretina J
      – PersonEntity:
          Name:
            NameFull: Caponigro G
      – PersonEntity:
          Name:
            NameFull: Porta DG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 04
              Text: 2023 Apr 25
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2211-1247
          Numbering:
            – Type: volume
              Value: 42
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Cell reports
              Type: main
ResultId 1